Sarcoidosis

HomePatientsLung Disease Week at the ATS2018 ▶ Sarcoidosis
Sarcoidosis Week

Sarcoidosis Week

Welcome to Sarcoidosis Week at ATS! Over 140 years ago Dr. Johnathon Hutchinson first described the cutaneous manifestations of sarcoidosis. A few years later in 1899, the term "sarcoidosis" was coined by Dr. Caesar Boeck and subsequently, in 1948, a Conference on Sarcoidosis convened and defined sarcoidosis as a "disease of unknown etiology". This definition for sarcoidosis, despite many years of research still prevails today. The diagnosis of sarcoidosis is established using clinical and radiologic findings alongside histologic evidence of noncaseating epithelioid-cell granulomas in the absence of organisms or particles. The incidence of sarcoidosis still varies by geographic location, likely because of varying environmental exposures, surveillance and diagnostic methods, and genetic factors like predisposing HLA alleles. Given these variations which may confound the true incidence rates, the highest annual incidence of sarcoidosis is thought to be in northern Europe, followed by the United States and then Japan. Sarcoidosis most commonly involves the skin, eyes and lungs which, interestingly, may suggest that airborne environmental pathogens, in part, play a role in its complex etiology. From a pulmonary standpoint, the respiratory symptoms often include cough, wheezing, dyspnea, and chest discomfort. Chest radiographs are used to classify sarcoidosis into four Scadding stages based on radiographic patterns, not disease chronicity or pulmonary function. The ATS and PAR's commitment to funding and promoting awareness of sarcoidosis makes this is an exciting time for sarcoidosis patients, clinicians, and researchers because new technologies and advances in genomics research will undoubtedly transform our understanding and lead to more specific diagnostic criteria and treatment options for this enigmatic disease.


 

Nkiruka Emeagwali M.S. M.D. Ph.D

Nkiruka Emeagwali M.S. M.D. Ph.D
Pulmonary and Critical Care Fellow, Yale PCCSM

Naftali Kaminski

Naftali Kaminski MD
Boehringer-Ingelheim Endowed Professor of Internal Medicine
Chief of Pulmonary, Critical Care and Sleep Medicine
Department of Medicine, Yale School of Medicine

Ginger Spitzer

Ginger Spitzer
Executive Director
Foundation for Sarcoidosis Research
Member, ATS Public Advisory Roundtable

 

ATS Sarcoidosis Partner
Foundation for Sarcoidosis Research

image

 

The Foundation for Sarcoidosis Research (FSR) is the nation's leading nonprofit organization dedicated to finding a cure for this disease and to improving care for sarcoidosis patients. Since its establishment in 2000, FSR has funded numerous domestic and international research efforts and has worked diligently to provide resources to thousands. FSR provides funding and collaborations for research and initiatives which focus on the understanding of sarcoidosis, addresses the causes of the disease, counters the suffering of patients, and advances the potential for a cure.